TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CYSTO-CONRAY II

IOTHALAMATE MEGLUMINE
Approved 1972-04-17
1
Indication
--
Phase 3 Trials
53
Years on Market

Details

Status
Prescription
First Approved
1972-04-17
Routes
INTRAVESICAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: IOTHALAMATE MEGLUMINE

CYSTO-CONRAY II Approval History

Loading approval history...

What CYSTO-CONRAY II Treats

1 indications

CYSTO-CONRAY II is approved for 1 conditions since its original approval in 1972. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cystourethrography
Source: FDA Label

CYSTO-CONRAY II Boxed Warning

NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE...

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CYSTO-CONRAY II FDA Label Details

Pro

Indications & Usage

Cysto-Conray II is indicated for use in retrograde cystography and cystourethrography.

โš ๏ธ BOXED WARNING

NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.